|
參考文獻
Acton PD, Choi SR, Hou C, Plossl K, Kung HF：Quantification of
serotonin transporters in nonhuman primates using [123I]ADAM and
SPECT. J Nucl Med. 42：1556–62, 2001.
Acton PD, Kung MP, Mu M, Plossl K, Hou C, and Siciliano M：Single
photon emission tomography imaging of serotonin transporters in
the non-human primate brain with the selective radioligand [123I]
IDAM. Eur J Nucl Med. 26：854-861, 1999.
Acton PD, Pilowsky LS, Plossl K, and Kung HF：Quantification of
dopamine transporter in the mouse brain using ultra-high reso- lution single photon emission tomography. Eur J Nucl Med. 29：
691–698, 2002.
Alvarez JC, Gluck N, and Arnulf I：Decrease platelet serotonin
transporter site and increased platelet inositol triphosphate
levels in patients with unipolar depression：effects of clomi- pramine and fluoxetine. Clin Pharmacol Ther. 66：617-624, 1999.
Baldwin RM, Zea-Ponce Y, Zoghbi SS, Laurelle M, al-Tikeiti MS,
Sybirska EH, Malison RT, Neumeyer JL, Milius RA, Wang S：Evaluation
of the monoamine uptake site ligand [123I]methyl 3beta-(4-
74
iodophenyl)-tropane-2beta-carboxylate ([123I]beta-CIT) in non- human primates：pharmacokinetics, biodistribution and SPECT brain
imaging coregistered with MRI. Nucl Med Biol. 20：597-606, 1993.
Bellivier F, Henry C, and Szoke A：Serotonin transporter gene poly- morphisms in patients with unipolar or bipolar depression. Neuro- sci Lett. 255：143-146, 1998.
Bligh-Glover W, Kolli TN, Shapiro-Kulnane L, Dilley GE, Friedman L,
Balraj E, Rajknowska G, and Stockmeier CA：The serotonin trans- porter in the midbrain of suicide victim with major depression.
Bio Psychiatry. 47：1015-1024, 2000.
Booij J, de Win MM：Brain kinetics of the new selective serotonin
transporter tracer [(123)I]ADAM in healthy young adults. Nucl Med
Biol. 33：185-91, 2006.
Booij J, Tissingh G, WinogrodzKa A, van Royen EA：Imaging of the dopa- minergic neurotransmission system using single-photon emission
tomography and positron emission tomography in patients with
parkinsonism. Eur J Nucl Med. 26：171-82, 1999.
Brooks DJ：Functional imaging in relation to parkinsonian syndromes.
J Neurol Sci. 115：1-17, 1993.
75
Carroll FI, Scheffel U, Dannals RF, Boja JW, Kuhar MJ：Development
of imaging agents for the dopamine transporter. Med Res Rev. 15：
419-44, 1995.
Catafau AM, Pe´rez V, Penego M, Bullich S, Danu´ s M, Puigdemont D：
SPECT of Serotonin Transporters Using 123I-ADAM：optimal imaging
time after bolus injection and long-term test–retest in healthy
volunteers. J Nucl Med. 46：1301–9, 2005.
Catafau AM：Brain SPECT of dopaminergic neurotransmission：a new tool
with proved clinical impact. Nucl Med Commun. 22：1059-60, 2001.
Chalon S, Bronquard C, Vercouillie J, Kodas E, Garreau L, Bodard S：
ADAM is an effective tool for in vivo study of serotonergic
function：validation in rat models. Synapse. 52：136–42, 2004.
Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM：serotoninergic
terminal transporters are differentially affected in parkinson＇s
disease and progressive supranuclear palsy：An autoradiographic
study with [H3]citalopram. Neuroscience. 54：691-9, 1993.
Choi SR, Hou C, Oya S, Mu M, Kung MP, Siciliano M, Acton PD, and Kung
HF：Selective in vitro and in vivo binding of [125I]ADAM to serotonin
transporters in rat brain. Synapse. 38：403-412. 2000.
76
Ciliax BJ, Heilman C, Demchyshyn LL：The dopamine Transporter：immuno- chemical characterization and localization in brain. J Neurosci.
15：1714-1723, 1994.
Collin M, Hakansson-Ovesjo M, Ogren SO, and Meister B：Decreased 5-HT
transporter mRNA in the dorsal raphe nucleus and behavioral
depression in the obese leptin-deficient ob/ob mouse. Brain Res
Mol. 81：51-61, 2000.
Cortes R, Soriano E, Pazos A, Probst A, Palacios JM：Autoradiography
of antidepressant binding sites in the human brain：localization
using [3H]imipramine and [3H]paroxetine. Neuroscience. 27：473–496,
1988.
Dean B, Opeskin K, and Pavery G：[3H]paroxetine binding is altered
in the hippocampus but not the frontal cortex or caudate nucleus
from subjects with schizophrenia. J Neurochem. 64：1197-1202, 1995.
Dean B, Pereira A, Pavey G, and Singh B：Repeated antidepressant drug
treatment, time of death and frequency of handing do not affect
[3H]paroxetine binding in rat cortex. Psychiatry Res. 73：173-179,
1997.
Farde L, Hallidin C, Muller L, Suhara T, Karlsson P, and Hall H：
77
PET study of [11C]beta-CIT binding to monoamine transporters in the
monkey and human brain. Synapse. 16：93-103, 1994.
Ferris RM, Brieaddy L, Methta N, Hollingsworth E, Rigdon G, Wang C,
Soroko F, Wastilia W, and Cooper B：Pharmacological properties of
403U76, a new chemical class of 5-hydroxytryptamine and nor- epinephrine reuptake inhibitor. J Pharm Pharmacol. 47：775-81,
1995.
Frokjaer VG, Pinborg LH, Madsen J, Knudsen GM：Evaluation of the
serotonin transporter ligand [123I]ADAM for SPECT studies in humans.
Eur J Nucl Med Mol Imaging. 31：S288, 2004.
Fuller RW：Mechanism and functions of serotonin neuronal system：
opportunities for neuropeptide interaction. Ann N Y Acad Sci. 780：
176-84, 1996.
Giros B, Caron MG：Molecular characterization of the dopamine
transporter. Trends Pharmacol Sci. 14：43-49, 1993.
Halldin C, Gulyas B, Langer O, Farde L：Brain radioligands-state of
the art and new trends. Q J Nucl Med. 45：139-52, 2001.
Huang WS, Ma KH, Cheng CY, Chen CY, Fu YK, Chou YH, Wey SP, Liu JC：
Imaging serotonin transporters with 123I-ADAM brain SPECT in healthy
78
non-human primates. Nucl Med Commun. 25：515-9, 2004.
Jacobs BL,and Azmitia EC：Structure and function of the brain
serotonin system. Physiol Rev. 72：165-229, 1992.
Jan Booij, Maartje M.L. de Win：Brain kinetics of the new selective
serotonin transporter tracer [123I]ADAM in healthy young adults.
Nucl Med Biol. 33：185-91, 2006.
Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE：
Serotonin uptake sites and serotonin receptors are altered in the
limbic system of schizophrenics. Neuropsychopharmacology. 8：
315-36, 1993.
Kasper S, Tauscher J, Kufferle B, Barnas C, Pezawas L, Quiner S：
Dopamine- and serotonin- receptors in schizophreni：results of
imaging studies and implications for pharmacotherapy in schizo- phrenia. Eur Arch Psychiatry Clin Neurosci. 249：83-9, 1999.
Kauppinen TA, Bergstrom KA, Heikman P, Hiltunen J, Ahonen AK：Bio- distribution an radiation dosimetry of [123I]ADAM in healthy human
subjects：preliminary results. Eur J Nucl Med Mol Imaging. 30：
132-6, 2003.
Kish SJ, Furukawa Y, Chang LJ, Tong JC, Ginovart N,Wilson A：Regional
79
distribution of serotonin transporter protein in postmortem human
brain is the cerebellum a SERT-free brain region? Nucl Med Biol.
32：123–8, 2005.
Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK：Imaging of
dopamine transporters in humans with technetium-99m TRODAT-1. Eur
J Nucl Med. 23：1527-30, 1996.
Kung MP, Hou C, Oya S, Acton PD, and Kung HF：Characterization of
[123I]IDAM as a novel single photon emission tomography tracer for
serotonin transporters. Eur J Nucl Med. 26：844-53, 1999.
Launay JM, Callebert J, Bondoux D, and Loric S：Serotonin receptor
and therapeutics. Cell Mol Biol (Noisy-le-grand). 40：327-36, 1994.
Laruelle M, Abi-Dargham A, van Dyck C, Gil R, D＇ Souza DC, Krystal
J, Seibyl J, Baldwin R, and Innis R：Dopamine and serotonin
transporters in patients with schizophrenia：an imaging study with
[123I]beta-CIT. Biol Psychiatry. 47：371-9, 2000.
Laruelle M, Baldwin RM, Malison RT, Zea-Ponce Y, Zoghbi SS,
alTikriti MS, Sybirska EH, Zimmermann RC, Wisniewski G, Neumeyer
JL：SPECT imaging of dopamine and serotonin transporters with [123I]
beta-CIT：pharmacological characterization of brain uptake in
80
non-human primates. Synapse. 13：295-309, 1993.
Lin KJ, Liu CY, Wey SP, Hsiao IT, Wu J, Fu YK, Yen TC：Brain SPECT
imaging and whole-body biodistribution with [(123)I]ADAM - a
serotonin transporter radiotracer in healthy human subjects. Nucl
Med Biol. 33：193-202, 2006.
Ma KH, Huang WS, Chen CH, Lin SZ, Wey SP, Ting G, Wang SD, Liu HW,
Liu JC：Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]
IBZM in normal and 6-OHDA lesioned formosan rock monkeys. Nucl Med
Biol. 29：561-7, 2002.
Mann JJ：The neurobiology of suicide. Nat Med. 4：25-30, 1998.
Marcisson JO, and Ross SB：Binding of some antidepressant to the
5-hydroxytryptamine transporter in the brain and platelets.
Psychopharmacol. 102：145-155, 1990.
Meegalla SK, Plossl K, Kung MP, Chumpradit S , Stevenson A, Frederick
D, Kung HF：Tc-99m-labeled tropane as dopamine transporter imagimg
agents. Bioconj Chem. 7：421-429, 1996.
Meegalla SK, Plossl K, Kung MP, Stevenson DA, Liable-sands L.M,
Rheingold A.L, Kung HF：First example of a 99mTC complex as a dopamine
transporter imagimg agent. J Am Chem Soc. 117：11037-8, 1995.
81
Meltzer CC, Smith G, DeKosky ST, Pollock BG, Mathis CA, Moore RY,
and Kupfer DJ：Serotonin in aging, late-life depression, and
Alzheimer＇s disease：the emerging role of functional imaging.
Neuropsychopharmacology. 18：407-30, 1998.
Meneses A：5-HT system and cognition. Neurosci Biobehav Rev. 23：
1111-1125, 1999.
Menza MA, Palermo B, DiPaola R, Sage JI, Ricketts MH：Depression and
anxiety in Parkinson's disease: possible effect of genetic
variation in the serotonin transporter. J Geriatr Psychiatry
Neurol. 12：49-52, 1999.
Morris ED, Babich JW, Alpert NM, Bonab AA, Livni E, Weise S, Hsu H,
Christian BT, Madras BK, Fischman AJ：Quantification of dopamine
transporter density in monkeys by dynamic PET imaging of multiple
injections of 11C-CFT. Synapse. 24：262-72, 1996.
Nagai M：The role of serotoninergic system in body temperature
regulation. Physiol Res. 41：65-69, 1992.
Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults
J：123I-ADAM binding to serotonin transporters in patients with major
depression and healthy controls：a preliminary study. J Nucl Med.
82
46：973–7, 2005.
Newberg AB, Plfssl K, Mozley PD：Biodistribution and imaging with
123I-ADAM：a serotonin transporter imaging agent. J Nucl Med. 45：
834–41, 2004.
Nic J. van der W, Henk S, Johannes AH, Rene CM, Damiaan A. Denys,
Harold J.van M, Rene＇s.K, Herman MW：Enhanced Dopamine Transporter
Density in Psychotropic-Naïve Patients With Obsessive-Compulsive
Disorder Shown by [123I]β-CIT SPECT. Am J Psychiatry. 161：2201-2206,
2004.
Owens MJ, and Nemeroff CB：The role of serotonin in the pathology
of depression：Focus on the serotonin transporter. Clin Chem. 40：
288-295, 1994.
Oya S, Choi SR, Hou C, Mu M, Kung MP, Acton PD, Siciliano M, Kung
HF：2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine
(ADAM)：an improved serotonin transporter ligand. Nucl Med Biol.
27：249-54, 2000.
Oya S, Kung MP, Acton PD, Mu M, Hou C, Kung HF：A new single-photon
emission computed tomography imaging agent for serotonin trans- porters：[123I]IDAM,5-iodo-2-((2-((dimethylamino)methyl)phenyl)
83
thio)benzyl alcohol. J Med Chem. 42：333-5, 1999.
Peroutka SJ：5-Hydroxytrytamine Receptors Subtype：Molecular,
Biochemical and Physiological Characterization. Trends Neuro. Sci.
11：496-500, 1988.
Peroutka SJ：5-Hydroxytryptamine Receptors. J Neurochem. pp.408-16,
1993.
Peroutka SJ, Snyder SH：Multiple serotonin receptor：differential
binding of [3H]-serotonin, [3H]-lysergic acid diacylamide and [3H]
spiroperidol. Mol Pharmacol. 16：687-699, 1979.
Pogarell O, Tatsch K, Juckel G, Hamann C, Mulert C, Popperl G,
Folkerts M, Chouker M, Riedel M, Moller HJ, Hegerl U：Serotonin
and dopamine transporter availabilities correlate with the loud- ness dependence of auditory evoked potentials in patients with
obsessive-compulsive disorder. Neuropsychopharmacology. 29：
1910-7,2004.
Richardson BP, and Engel G：The pharmacology and Function of 5HT3
Receptors. Trend Neuro. sci. pp.424-8, 1986.
Ross SB：The characteristics of serotonin uptake system. In：Osbrone
NN (ed) Biology of serotonergic transmission. Wiley Chichester.
84
pp.159-195, 1982.
Seeman P, Chau-Wong M, Tedesco J, Wong K：Brain receptors for anti- psychotic drugs and dopamine：direct binding assays. Proc Natl Acad.
Sci. U.S.A. 72：4376-80, 1975.
Scheffel U, Kim S, Cline EJ, and Kuhar MJ：Occupancy of the serotonin
transporter by fluoxetine, paroxetine, and sertraline：in vivo
studies with [125I]RTI-55. Synapse. 16：263-268, 1994.
Staley JK, Krishnan-Sarin S, Zoghbi S, Tamagnan G, Fujita M, Seibyl
JP, Maciejewski PK, O＇Malley S：serotonin transporter
availability in healthy smokers and nonsmokers. Synapse. 41：275-84,
2001.
Staley JK, Malison RT, and Innis RB：Imaging of serotonergic system：
interactions of neuroanatomical and functional abnormalities of
depression. Biol Psychiatry. 44：534-549, 1998.
Stoessl AJ, Ruth TJ：Neuroreceptor imaging：new developments in PET
and SPECT imaging of neuroreceptor binding (including dopamine
transporters, vesicle transporters and post synaptic receptor
sites). Curr Opin Neurol. 11：327-33, 1998.
Szabo Z, Kao PF, Scheffel U, Suehiro M, Mathews WB, Ravert HT,
85
Musachio JL, Marenco S, Kim SE, Ricaurte GA：Positron emission
tomography imaging of serotonin transporters in the human brain
using [11C](+)McN5652. Synapse. 20：37-43, 1995.
Tatsch K：Imaging of the dopaminergic system in parkinsonism with
SPET. Nucl Med Commun. 22：819-27, 2001.
Tejani-Butt SM, Yang J, Pawlyk AC：Altered serotonin transporter
sites in Alzheimer＇s disease raphe and hippocampus. NeuroReport.
6：1207-10, 1995.
Van Dyck CH, Malison RT, Seibyl JP, Laruelle M, Klumpp H, Zoghbi SS：
Age-related decline in central serotonin transporter availability
with [123I]h-CIT SPECT. Neurobiol Aging. 21：497– 501, 2000.
Volkow ND, Fowler JS, Gatley SJ：PET evaluation of the dopamine system
of the human brain. J Nucl Med. 37：1242-1256, 1996.
Wijngaarden IV, Tulp M, and Soudijn W：The concept of selectivity
in 5-HT receptor reserch. Eur J Pharmacol. 188：301-12, 1990.
Willeit M, Praschak-Rieder N, and Neumeister A：[123I]-beta-CIT SPECT
imaging shows reduced brain serotonin transporter availability in
drug-free depressed patients with seasonal affective disorder.
Biol Psychiat. 47：482-489, 2000.
86
Willian FG：Ganing,Review of medical physiology. Ho-Chi Book
Publishing com., Taiwan, pp.120-123, pp.299-300, 1998.
Ye XX, Chen JC, Liu RS：Microautoradiography of [123I]ADAM in mice
treated with fluoxetine and serotonin reuptake inhibitors. Nucl
Med Biol. 31：557–62, 2004.
Ye XX, Hwang JJ, Hsieh JF, Chen JC, Chou YT, Tu KY, Wey SP, Ting G：
In vivo quantification by SPECT of [123I]ADAM bound to serotonin
transporters in the brains of rabbits. Nucl Med Biol. 31：995-1003,
2004.
Zanardi R, Benedetti F, Di Bella D, Catalano M, and Smeraldi E：
Efficacy of paroxetine in depression is influenced by a functional
polymorphism within the promoter of the serotonin transporter gene.
J Clin Psychopharmacol. 20：105-107, 2000.
Zea-Ponce Y, Baldwin RM, and Stratton MD：Radiosynthesis and PET
imaging of [N-methyl-11C]LY257327 as a tracer for 5-HT transporters.
Nucl Med Biol. 24：251-254, 1997.
陳永斌：以類巴金森氏症大白鼠模式探討人類多能性間葉系幹細胞在細胞
治療之應用. 東華大學生物技術研究所碩士論文，2004。
范國賢,孫英玲,徐維荃,李德偉,丁幹：PET 核醫藥物簡介. 核醫會訊. 第八
87
卷. 第三期, 2001.
|